PTC THERAPEUTICS, INC.
PTCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PTCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTCT
PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare disorders, with approved products including Translarna, Emflaza, and Kebilidi, and a pipeline in neurology and metabolic diseases.
Key risk: Clinical and regulatory uncertainty
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 10 pipeline candidates · 20 clinical trials · 5 catalysts for PTC THERAPEUTICS, INC..
PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare disorders, with approved products including Translarna, Emflaza, and Kebilidi, and a pipeline in neurology and metabolic diseases.
- PTC Therapeutics has approved products Translarna, Emflaza, and Kebilidi, with Kebilidi commercially launched in the U.S. [sec · filed 2026-04-20]
- The company entered a License and Collaboration Agreement with Novartis for its PTC518 Huntington's disease program, receiving a $1.0 billion upfront cash payment [sec · filed 2025-04-30]
- Cash, cash equivalents, and marketable securities were over $1.1 billion as of December 31, 2024 [sec · filed 2025-04-30]
- As of June 30, 2026, the company reported cash and equivalents of $1,066.3M, total revenue of $360.5M, and net income of $83.5M [sec]
- The company plans to initiate the PROVE-FA open label study for vatiquinone in Friedreich's ataxia in the third quarter of 2026, following FDA feedback [sec_mda · as of 2026-07-30]
What works
- Strong cash position of over $1.1 billion as of December 31, 2024, providing financial flexibility for operations and pipeline development [sec · filed 2025-04-30]
- Successful in-licensing and partnership strategy, including the Novartis collaboration for PTC518, which generated a $1.0 billion upfront payment [sec · filed 2025-04-30]
- Commercial successes for Translarna and Emflaza despite market headwinds, demonstrating product portfolio strength [sec · filed 2025-04-30]
What to weigh
- The successful development of products and product candidates is highly uncertain due to numerous risks in clinical trials, regulatory approval, and commercialization [sec_mda · as of 2026-07-30]
- The FDA suggested an additional study for vatiquinone to support NDA resubmission, indicating potential delays or increased costs [sec_mda · as of 2026-07-30]
- The company has negative shareholders' equity of -$205.3M as of June 30, 2026, reflecting accumulated losses [sec]
From the filings
Quoted directly from source documents.
PTC has a strong cash position from partnerships and operations
“Effective management of operating expenses enabling strong position of over $1.1 billion in cash, cash equivalents and marketable securities at December 31, 2024”
SEC filings · April 30, 2025
The Novartis collaboration provided significant upfront payment
“entered into a License and Collaboration Agreement with Novartis Pharmaceuticals Corporation, or Novartis, relating to our PTC518 Huntington's disease, or HD, program, which included the Company receiving an upfront cash payment of $1.0 billion”
SEC filings · April 30, 2025
FDA requested additional study for vatiquinone
“We met with the FDA in the fourth quarter of 2025 to discuss the vatiquinone development program, at which time the FDA suggested an additional study be conducted to support NDA resubmission.”
SEC MD&A · July 30, 2026
Development success is highly uncertain
“The successful development of our products and product candidates is highly uncertain.”
SEC MD&A · July 30, 2026
Catalyst timeline
- 2026-08-31 · Phase 2 Start: A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess — Initiation of a Phase 2A proof-of-concept study, which will provide early efficacy and safety data.
- 2027-12-31 · Phase 3 Topline: Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedre — Topline results from a long-term open-label study of vatiquinone for Friedreich's ataxia, critical for NDA resubmission.
- 2029-03-15 · Phase 3 Topline: Evaluation of Long-Term Efficacy of Vatiquinone for the Treatment of Friedreich's Ataxia — Further long-term efficacy data for vatiquinone, supporting potential regulatory filing.
- 2031-02-28 · Phase 3 Topline: A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Tr — Topline results from a study on neurocognitive outcomes in children with PKU, expanding the pipeline.
Risks & what to watch (3)›
Key risks
- Clinical and regulatory uncertainty — Development of products is highly uncertain due to risks in clinical trials, regulatory approval, and commercialization [sec_mda · as of 2026-07-30]
- Vatiquinone NDA delay risk — FDA suggested an additional study for vatiquinone, potentially delaying NDA resubmission and increasing costs [sec_mda · as of 2026-07-30]
- Negative shareholders' equity — Shareholders' equity was -$205.3M as of June 30, 2026, indicating accumulated losses exceeding equity [sec]
What to watch
- Initiation of the PROVE-FA open label study for vatiquinone in Friedreich's ataxia in Q3 2026 [sec_mda · as of 2026-07-30]
- Progress of the Novartis collaboration for PTC518 in Huntington's disease [sec · filed 2025-04-30]
- Commercial performance of Kebilidi in the U.S. following its launch [sec · filed 2026-04-20]
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PTC THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PTC THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $129M · Net income $83M
Lead: Approved
10 candidates
5 upcoming, next in ~1d
0 buys · 69 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
351
Total value held
$7.22B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 14,386,866 | $980.0M |
| blackrock, inc. | 12,948,717 | $882.2M |
| rtw investments, lp | 7,746,415 | $527.8M |
| vanguard capital management llc | 7,352,512 | $500.9M |
| vanguard portfolio management llc | 4,804,594 | $327.3M |
| state street corp | 4,346,519 | $296.1M |
| wellington management group llp | 3,942,610 | $268.6M |
| toronto dominion bank | 3,025,963 | $206.2M |
| armistice capital, llc | 2,464,449 | $167.9M |
| geode capital management, llc | 2,209,954 | $150.6M |
Showing top 10 of 351 institutional holders of PTC THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 13.0%
- Days to cover
- 7.8
- Shares short
- 9,452,081
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PTCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for PTC THERAPEUTICS, INC.?
PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare disorders, with approved products including Translarna, Emflaza, and Kebilidi, and a pipeline in neurology and metabolic diseases.
What is PTC THERAPEUTICS, INC.'s lead drug candidate?
PTC THERAPEUTICS, INC.'s most advanced tracked candidate is Emflaza (Approved) for Duchenne muscular dystrophy (DMD).
What is PTC THERAPEUTICS, INC.'s next catalyst?
PTC THERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess" — expected August 31, 2026.
Who is the CEO of PTC THERAPEUTICS, INC.?
Dr. Matthew B. Klein F.A.C.S., M.D., M.S. is the chief executive officer of PTC THERAPEUTICS, INC. (PTCT).
Where is PTC THERAPEUTICS, INC. headquartered?
PTC THERAPEUTICS, INC. (PTCT) is headquartered in Warren, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.